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Hyper IgE Syndrome (HIES) is an immunodeficiency disorder characterized by increased serum levels of IgE, eczema, and
recurrent cutaneous and pulmonary infections. In this report, we present, to our knowledge, the first documented case of renal
cell carcinoma (RCC) found in a patient with HIES. The patient received infectious disease clearance prior to obtaining a partial
nephrectomy which revealed clear cell histology. Both HIES and RCC have an immunological basis for their pathophysiology and
may involve common pathways. Further studies may provide insight into any possible link and clinicians should be mindful of
immunocompromised patients who present with risk factors for genitourinary malignancy.

1. Introduction

2. Case Report

The Hyperimmunoglobulin E Syndromes (HIES) are rare primary immune deficiencies that are characterized by the triad
of elevated serum IgE, rash, and recurrent bacterial infections of the skin and lung [1]. The incidence of HIES is expected to be 1 per 1,000,000. The disease was initially referred
to as Job’s syndrome, with reference to Biblical Job who was
“smote with boils.” The autosomal dominant form is caused
by mutations in the STAT3 gene which is a major signal transduction protein involved in wound healing, angiogenesis,
immune pathways, and cancer [2]. It is characterized by nonimmunologic features such as skeletal, connective, and pulmonary abnormalities [1]. The autosomal recessive form
is associated with viral and neurologic complications but
otherwise is not well understood. Malignancies associated
with Hyper Ig E Syndrome include Hodgkin’s and Non-Hodgkin’s lymphoma, as well as leukemia and those of the vulva,
liver, and lung [3]. Here we present a case report of a patient
with Hyper Ig E Syndrome and renal cell carcinoma. RCC
represents a common and aggressive form of kidney cancer
with approximately 64,000 new cases and 14,000 deaths
per year within the United States [4]. This to our knowledge is the first case report showing manifestation of both
conditions.

A 56-year-old male was found to have a 4 cm exophytic
right lower pole lesion upon work-up for complaints of back
pain. The CT scan performed demonstrated enhancement
(>20 HU) of the lesion and was suspicious for renal cell
carcinoma as seen in Figures 1 and 2.
His comorbidities included a history of Autosomal Dominant Hyper IgE (Job’s) Syndrome, sickle cell trait, alcoholic
liver disease, avascular necrosis of the hip, polysubstance
abuse, and depression. The patient described a history of
recurrent skin infections with formation of multiple abscesses
since he was a young child. These skin infections were managed both medically with the use of antibiotics and surgically
with incision and drainage. He also had a history of respiratory infections consistent with his Hyper Ig E Syndrome. The
patient continues to suffer from recurrent dental abscesses
for which he requires tooth extractions and receives topical
treatment for his HIES dermatitis. Serum IgE levels at the
time of his malignancy work-up were found to be within
normal limits. It had been over 10 years since the patient had
engaged in any drug or alcohol abuse; however, given his
alcoholic liver disease and HIES, he was at high risk for
immunodeficiency. Appropriate work-up further revealed
that the patient did not have human immunodeficiency virus
and hepatitis B or C.
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Figure 1: Axial image showing right kidney lower pole 4 cm renal
mass with enhancement.

Figure 2: Coronal image of delayed phase demonstrating exophytic
renal lesion within the right lower pole of the kidney.

Treatment options were discussed with the patient
including biopsy of the lesion, surgical intervention with
partial/radical nephrectomy, and ablative procedures. The
patient elected to undergo partial nephrectomy for treatment
and diagnosis of the lesion. His preoperative work-up
included medical as well as infectious disease clearance due to
his immunocompromised state. Infectious disease consultation recommended standard preoperative surgical prophylaxis as the patient had no ongoing infection at the time of
surgical planning.
Open partial nephrectomy was performed without any
intraoperative complications and pathology of the specimen
revealed pT1bNxMx clear cell renal carcinoma with Fuhrman
Grade 2. The tumor was 4.1 cm in size and did not exhibit any
sarcomatoid features and the tumor margins were negative.

3. Discussion
Hyper IgE Syndrome is associated with immunologic complications such as rash, boils, pneumonia, eczema, and
lymphoma while nonimmunologic complications include
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characteristic facies, retained primary teeth, and joint hyperextensibility [1]. Malignancies such as lymphoma have been
described, but there are no documented reports of an association with renal cell carcinoma. Renal cell carcinoma has been
found to be associated with the immunodeficiency disorder
chromosome 22q11 deletion syndrome [5].
Within the past two decades, immunotherapy has played
a role in the treatment of renal cell carcinoma based on the
infiltration of cancer tissue by tumor specific immune cells,
specifically dendritic cells, T cells, natural killer cells, and
macrophages [6, 7]. While T cells and natural killer cells play
a role in the eradication of tumors, dendritic cells have the
capacity to induce immunity or tolerance depending on their
differentiation. Dendritic cells exhibit characteristics related
to tumor immunoescape with high levels of matrix metalloproteinase-9 (MMP-9) and are known to promote tumor
cell proliferation through promotion of TNF𝛼 and limited
recruitment of TH 1 polarized lymphocytes [8]. These immunological changes highlight the importance of immunotherapy as a key player in the management of metastatic renal cell
carcinoma with various approaches such as cytokine-, antigen-, or dendritic cell-based immunotherapy [9].
With regard to HIES, the STAT3 gene when mutated affects signal transduction for many cytokines and growth factors that are responsible for cell survival, proliferation, migration, apoptosis, and inflammation in diverse cell types such as
keratinocytes, hepatocytes, thymic epithelial cells, respiratory
epithelial cells, neurons, lymphocytes, and macrophages [10].
It has also been demonstrated that impairment of interleukin
17 producing T helper cells (Th17) and induced regulatory
T cells may account for the immunological abnormalities of
HIES [11]. Mutations in the FOXP3 gene have also shown to
play a role in immunodeficiency disorders.
In this report, we present a case describing the presentation of renal cell carcinoma in a patient with Hyper IgE
Syndrome. Our patient presented with a long standing history
of Hyper IgE Syndrome and its associated complications
such as recurrent skin, dental, and pulmonary infections.
Interestingly, during the time of our work-up his IgE levels
were within normal limits which is a common finding in
HIES patients as adults [12]. There is currently no evidence
of a direct link between HIES and RCC, but immunological
factors relevant to each condition may account for a possible
association that has not yet been recognized. Recent studies
have demonstrated an increase in infiltrating Th17 and FoxP3
cells within the tumor milieu of renal cell carcinoma [13, 14].
Given the relationship seen in both of these immunological disorders with a role being played by Th17 and FoxP3 it is
possible that patients with these mutations and perhaps disorders may be at increased risk for development of renal cell
carcinoma along with already well-established malignancies.
Hypoxia Inducible Factor-1 (HIF-1) may also provide a key
link between these two disorders. Studies have shown that
HIF-1 regulated lysyl oxidase (LOX) is upregulated in vitro
in cells infected with Staphylococcus aureus as well as in vivo
in murine renal abscess and human skin abscess models [15].
Furthermore, LOX mRNA is increased in human clear cell
renal cell carcinoma and is associated with decreased overall
and metastasis-free survival [16].
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Further research and studies need to be performed to
delineate the immunological nature of malignant disease and
any possible relationship with immunodeficiency disorders
that has not yet been defined. Our findings present the need
for careful consideration of RCC in immunodeficient patients
presenting with risk factors, as well as the need for careful
preoperative clearance and perioperative management to prevent unwarranted infectious complications.

4. Conclusion
Our findings demonstrate to our knowledge the first case presentation of renal cell carcinoma in a patient with Hyper Ig
E Syndrome. Critical immunological factors play a role in
the pathophysiology of each disease and may provide insight
into a possible link between the disorders and further study is
needed to delineate any shared immunological changes.
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